Hosein Ameri, Brendan Mulhern, Richard Norman, Takeru Shiroiwa, Rajabali Daroudi, Thomas G Poder
{"title":"A cross-country comparison of the psychometric performance of SF-6Dv2 and EQ-5D-5L.","authors":"Hosein Ameri, Brendan Mulhern, Richard Norman, Takeru Shiroiwa, Rajabali Daroudi, Thomas G Poder","doi":"10.1007/s10198-025-01867-3","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the comparative performance of SF-6Dv2 and EQ-5D-5L in the general population of Quebec (Canada), Tehran (Iran), and Japan.</p><p><strong>Methods: </strong>Data on SF-6Dv2 and EQ-5D-5L were collected in the three countries. Descriptive differences in utility values between SF-6Dv2 and EQ-5D-5L were assessed using t-tests, as well as ceiling effects were evaluated based on the percentage of \"no problem\" levels reported. The known-group validity of both measures was assessed by comparing utility scores across health and demographic subgroups using t-tests or ANOVA and by calculating effect sizes across known groups. The area under the receiver operating characteristic curve (AUROC) analysis and F-statistic ratios were used to further validate the findings from the known-group validity analyses. Convergent validity for both instruments was assessed using Spearman's rank correlation coefficient. The agreement between instruments was evaluated using intraclass correlation coefficients (ICC) and Bland-Altman plots.</p><p><strong>Results: </strong>A total of 2,378 respondents for Quebec, 3,061 for Tehran, and 3,933 for Japan were included. Differences in utility values between SF-6Dv2 and EQ-5D-5L were statistically significant, with SF-6Dv2 generally yielding lower utility scores. Both instruments demonstrated strong known-group validity, effectively distinguishing between diseased and healthy groups as well as various demographic characteristics. However, EQ-5D-5L outperformed SF-6Dv2 for most demographic characteristics based on AUROC analysis and F-statistic ratios. In contrast, their performance in distinguishing between healthy and diseased groups did not favor a particular instrument. Convergent validity analyses indicated strong associations between SF-6Dv2 and EQ-5D-5L utility values in Quebec (0.760) and Tehran (0.737). The agreement between SF-6Dv2 and EQ-5D-5L utility values was moderate in Quebec (0.69) and strong in Tehran (0.837). Bland-Altman plots indicated that differences between the two instruments tended to increase as the average score decreased.</p><p><strong>Conclusion: </strong>Both EQ-5D-5L and SF-6Dv2 demonstrated favorable psychometric performance in terms of known-group validity and convergent validity. These findings suggest that both instruments are valid tools for health utility measurement for use in general population.</p>","PeriodicalId":51416,"journal":{"name":"European Journal of Health Economics","volume":" ","pages":"1073-1085"},"PeriodicalIF":3.1000,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Health Economics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10198-025-01867-3","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/12/5 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ECONOMICS","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: To evaluate the comparative performance of SF-6Dv2 and EQ-5D-5L in the general population of Quebec (Canada), Tehran (Iran), and Japan.
Methods: Data on SF-6Dv2 and EQ-5D-5L were collected in the three countries. Descriptive differences in utility values between SF-6Dv2 and EQ-5D-5L were assessed using t-tests, as well as ceiling effects were evaluated based on the percentage of "no problem" levels reported. The known-group validity of both measures was assessed by comparing utility scores across health and demographic subgroups using t-tests or ANOVA and by calculating effect sizes across known groups. The area under the receiver operating characteristic curve (AUROC) analysis and F-statistic ratios were used to further validate the findings from the known-group validity analyses. Convergent validity for both instruments was assessed using Spearman's rank correlation coefficient. The agreement between instruments was evaluated using intraclass correlation coefficients (ICC) and Bland-Altman plots.
Results: A total of 2,378 respondents for Quebec, 3,061 for Tehran, and 3,933 for Japan were included. Differences in utility values between SF-6Dv2 and EQ-5D-5L were statistically significant, with SF-6Dv2 generally yielding lower utility scores. Both instruments demonstrated strong known-group validity, effectively distinguishing between diseased and healthy groups as well as various demographic characteristics. However, EQ-5D-5L outperformed SF-6Dv2 for most demographic characteristics based on AUROC analysis and F-statistic ratios. In contrast, their performance in distinguishing between healthy and diseased groups did not favor a particular instrument. Convergent validity analyses indicated strong associations between SF-6Dv2 and EQ-5D-5L utility values in Quebec (0.760) and Tehran (0.737). The agreement between SF-6Dv2 and EQ-5D-5L utility values was moderate in Quebec (0.69) and strong in Tehran (0.837). Bland-Altman plots indicated that differences between the two instruments tended to increase as the average score decreased.
Conclusion: Both EQ-5D-5L and SF-6Dv2 demonstrated favorable psychometric performance in terms of known-group validity and convergent validity. These findings suggest that both instruments are valid tools for health utility measurement for use in general population.
期刊介绍:
The European Journal of Health Economics is a journal of Health Economics and associated disciplines. The growing demand for health economics and the introduction of new guidelines in various European countries were the motivation to generate a highly scientific and at the same time practice oriented journal considering the requirements of various health care systems in Europe. The international scientific board of opinion leaders guarantees high-quality, peer-reviewed publications as well as articles for pragmatic approaches in the field of health economics. We intend to cover all aspects of health economics:
• Basics of health economic approaches and methods
• Pharmacoeconomics
• Health Care Systems
• Pricing and Reimbursement Systems
• Quality-of-Life-Studies The editors reserve the right to reject manuscripts that do not comply with the above-mentioned requirements. The author will be held responsible for false statements or for failure to fulfill the above-mentioned requirements.
Officially cited as: Eur J Health Econ